GlassScriptPhysician profile
Eileen A Knox
NPI 1831523638
$8,269.58
in general payments reported to CMS, 2019-2025
36 companies · $79.69 in 2025
The $79.69 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,655 · 2022: $2,229 · 2023: $2,725 · 2024: $580 · 2025: $79.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,292 · Education: $92.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,292.10 |
| Education | $92.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,397.32 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $585.74 | 2021-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $577.65 | 2021-2024 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $569.38 | 2021-2024 | |
| Novo Nordisk INC | $568.15 | 2021-2023 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $509.50 | 2021-2024 | Jardiance |
| Lilly USA, LLC | $470.66 | 2021-2023 | Jardiance, Mounjaro, Emgality |
| Astrazeneca Pharmaceuticals LP | $457.20 | 2021-2024 | Breztri, Airsupra, Farxiga |
| Amarin Pharma, INC. | $412.30 | 2021-2023 | |
| Abbvie INC. | $354.17 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $325.45 | 2021-2024 | Verquvo, Belsomra, Gardasil |
| Janssen Pharmaceuticals, INC | $297.74 | 2021-2022 | |
| Amgen INC. | $291.11 | 2021-2023 | Repatha, Otezla |
| Pfizer INC. | $251.20 | 2022-2024 | |
| Kowa Pharmaceuticals America, INC. | $164.42 | 2021-2022 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eileen Knox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.